UKHSA review finds sparse evidence on maternal pertussis vaccination and infant pneumococcal carriage
A rapid systematic review from the UK Health Security Agency examined whether maternal pertussis vaccination influences pneumococcal carriage in infants who later receive a pneumococcal conjugate vaccine. The question is clinically narrow, but it sits at the intersection of maternal immunization policy and early-life respiratory infection prevention, where even small shifts in microbial colonization can shape downstream disease risk. The review searched research published up to 4 June 2026 and identified seven studies, including an individual participant data meta-analysis.
The timing of this question matters because the infant airway is not a static environment. In the first months of life, carriage of respiratory pathogens is shaped by maternal antibodies, infant vaccination schedules, feeding patterns, exposure intensity, and the immature mucosal immune system. Pertussis vaccination in pregnancy is designed to protect against Bordetella pertussis, yet the review asks a different and more specific question: whether that maternal intervention also alters the likelihood that infants carry Streptococcus pneumoniae after receiving pneumococcal conjugate vaccination.
A narrow question with broad prevention consequences
Pneumococcal carriage is not the same as invasive disease, but it remains a meaningful surveillance endpoint because colonization precedes transmission and can precede infection. In infants, any intervention that changes carriage patterns can affect household spread, daycare exposure dynamics, and the background ecology of respiratory pathogens. The review therefore addresses a biologically plausible concern: maternal vaccination might influence the infant immune milieu in ways that could either dampen or unintentionally alter later responses to another vaccine-preventable organism.
Seven studies is a small evidence base for a public health question with potentially wide policy relevance. Even so, the inclusion of an individual participant data meta-analysis gives the review a more granular analytic foundation than a simple study-level synthesis would provide. Individual participant data can help align outcome definitions, timing windows, and subgroup analyses across studies, which is especially valuable when the endpoint is carriage rather than a hard clinical event such as hospitalization or invasive pneumococcal disease.
One result stands out before any deeper inference is drawn: the evidence base remains limited.
Why the biology is plausible but not settled
Maternal pertussis vaccination primarily works through transplacental antibody transfer and protection against severe pertussis in early infancy. Those same maternal antibodies can shape early antigen exposure, immune priming, and the trajectory of infant responses to later vaccines. In theory, that immune modulation could influence nasopharyngeal colonization indirectly, because pneumococcal carriage depends on the balance between mucosal immunity, microbial competition, and host susceptibility.
Yet plausibility is not proof. No mechanism in this review can be treated as established from the summary alone, and the available evidence was assembled specifically to determine whether any measurable effect on infant pneumococcal carriage had emerged in studies of infants who had received pneumococcal conjugate vaccination. The review’s design signals caution rather than certainty: it gathers and appraises a small body of literature instead of claiming a definitive answer.
In practical terms, that means clinicians should not infer a carriage effect from maternal pertussis vaccination unless the underlying studies show one. A vaccine given to prevent one pathogen should not be assumed to remodel colonization by another without direct evidence.
What seven studies can and cannot say
The review included seven studies, but the public summary does not provide the individual study designs, sample sizes, carriage definitions, or effect estimates. Those missing details are not a flaw in the review itself; they are a limitation of the source material available here. They also matter because carriage outcomes are highly sensitive to how investigators sample the nasopharynx, when they sample it, and which laboratory methods they use to detect pneumococcal colonization.
A study of carriage can change meaning depending on whether investigators measure any carriage, density of carriage, serotype-specific carriage, or carriage at a single time point after vaccination. The infant age window also affects interpretation, because colonization pressure rises and falls quickly in the first year of life. Without those details, the safest conclusion is a restrained one: the review identified a small evidence base, and it was sufficiently structured to include an individual participant data meta-analysis, but the summary does not support broad clinical claims beyond that.
This is exactly the sort of question that can become overinterpreted if the evidence is treated as more mature than it is. The data are enough to justify synthesis, not enough to justify certainty.
Policy relevance for maternal immunization programs
Maternal pertussis vaccination remains a major preventive strategy in pregnancy, and the review does not present any reason to change that position. Its value lies in mapping whether collateral effects on infant pneumococcal carriage have been studied at all, and in what form. Public health programs often need that kind of evidence before assuming that one immunization policy is neutral, beneficial, or potentially interactive with another.
The infant pneumococcal vaccine schedule adds a second layer of complexity. Once infants receive pneumococcal conjugate vaccination, any observed carriage outcome reflects the combined effects of maternal antibodies, infant vaccination, and natural exposure. Separating those influences is difficult, which is why the inclusion of participant-level data can be useful. It allows analysts to compare infants more consistently across studies and may help detect patterns that would be obscured in aggregate reporting.
Still, the current review summary does not reveal whether the synthesized evidence points toward harm, benefit, or no detectable effect. That absence of detail keeps the clinical message appropriately conservative: the question has been studied, but the public summary does not provide enough information to redraw practice.
Evidence gaps remain the central finding
The most important fact in this update is not a dramatic signal in either direction. It is the thinness of the evidence base itself. Seven studies, even with an individual participant data meta-analysis among them, leave substantial room for uncertainty about how maternal pertussis vaccination intersects with infant pneumococcal carriage after conjugate vaccination.
Future work will need to answer several practical questions: whether carriage effects differ by infant age, whether serotype distribution changes, whether timing of sampling alters apparent findings, and whether any effect is consistent across settings with different transmission pressure. The review identifies the question cleanly. It does not yet close it.